-
1
-
-
24944494962
-
A process for measuring the quality of cancer care: The Quality Oncology Practice Initiative
-
Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol. 2005;23:6233-39.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6233-6239
-
-
Neuss, M.N.1
Desch, C.E.2
McNiff, K.K.3
-
2
-
-
4143132329
-
Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality
-
Schneider EC, Epstein AM, Malin JL, et al. Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol. 2004;22:2985-91.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2985-2991
-
-
Schneider, E.C.1
Epstein, A.M.2
Malin, J.L.3
-
3
-
-
12444272754
-
Medicare demonstration projects acknowledge evidence-based medicine in cancer care
-
Twombly R. Medicare demonstration projects acknowledge evidence-based medicine in cancer care. J Natl Cancer Inst. 2005;97:6-7.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 6-7
-
-
Twombly, R.1
-
4
-
-
0037291748
-
Outcomes research at the National Cancer Institute: Measuring, understanding, and improving the outcomes of cancer care
-
Lipscomb J, Donaldson MS. Outcomes research at the National Cancer Institute: measuring, understanding, and improving the outcomes of cancer care. Clin Ther. 2003;25:699-712.
-
(2003)
Clin Ther
, vol.25
, pp. 699-712
-
-
Lipscomb, J.1
Donaldson, M.S.2
-
5
-
-
4444367159
-
Bridging the divide: Integrating cancer-directed therapy and palliative care
-
Malin JL. Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol. 2004;22:3438-40.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3438-3440
-
-
Malin, J.L.1
-
6
-
-
0043211860
-
National Institutes of Health State-of-the-Science Panel
-
July 15-17, J Natl Cancer Inst
-
Patrick D, Ferketich S, Frame P, et al. National Institutes of Health State-of-the-Science Panel. National Institutes of Health State-of-the-Science conference statement: symptom management in cancer: pain, depression, and fatigue; July 15-17, 2002. J Natl Cancer Inst. 2003;95:1110-17.
-
(2002)
National Institutes of Health State-of-the-Science conference statement: Symptom management in cancer: pain, depression, and fatigue
, vol.95
, pp. 1110-1117
-
-
Patrick, D.1
Ferketich, S.2
Frame, P.3
-
7
-
-
0042259168
-
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy
-
Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2003;23:15S-19S.
-
(2003)
Pharmacotherapy
, vol.23
-
-
Crawford, J.1
-
8
-
-
27744493302
-
Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence
-
Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw. 2005;3:557-71.
-
(2005)
J Natl Compr Canc Netw
, vol.3
, pp. 557-571
-
-
Lyman, G.H.1
-
9
-
-
0028909867
-
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
-
Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-06.
-
(1995)
N Engl J Med
, vol.332
, pp. 901-906
-
-
Bonadonna, G.1
Valagussa, P.2
Moliterni, A.3
-
10
-
-
11344273935
-
Dose and schedule as determinants of outcomes in chemotherapy for breast cancer
-
Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol. 2004;31 (suppl 15):3-9.
-
(2004)
Semin Oncol
, vol.31
, Issue.SUPPL. 15
, pp. 3-9
-
-
Budman, DR.1
-
11
-
-
11344274427
-
The importance of chemotherapy dose intensity in lung cancer
-
Crawford J. The importance of chemotherapy dose intensity in lung cancer. Semin Oncol. 2004;31(suppl 15):25-31.
-
(2004)
Semin Oncol
, vol.31
, Issue.SUPPL. 15
, pp. 25-31
-
-
Crawford, J.1
-
12
-
-
0025363033
-
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
-
Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-77.
-
(1990)
J Clin Oncol
, vol.8
, pp. 963-977
-
-
Kwak, L.W.1
Halpern, J.2
Olshen, R.A.3
-
13
-
-
0027495838
-
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte)
-
Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993;4:651-56.
-
(1993)
Ann Oncol
, vol.4
, pp. 651-656
-
-
Lepage, E.1
Gisselbrecht, C.2
Haioun, C.3
-
14
-
-
17644379037
-
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
-
Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy Cancer. 2005;103: 1916-24.
-
(2005)
Cancer
, vol.103
, pp. 1916-1924
-
-
Caggiano, V.1
Weiss, R.V.2
Rickert, T.S.3
-
15
-
-
0025800331
-
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
-
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
-
(1991)
N Engl J Med
, vol.325
, pp. 164-170
-
-
Crawford, J.1
Ozer, H.2
Stoller, R.3
-
16
-
-
0037250159
-
A randomized double-blind multi-center phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
-
Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multi-center phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol. 2003;14:29-35.
-
(2003)
Ann Oncol
, vol.14
, pp. 29-35
-
-
Green, M.D.1
Koelbl, H.2
Baselga, J.3
-
17
-
-
0027390482
-
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
-
Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-24.
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 319-324
-
-
Trillet-Lenoir, V.1
Green, J.2
Manegold, C.3
-
18
-
-
14544270307
-
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
-
Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-84.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1178-1184
-
-
Vogel, C.L.1
Wojtukiewicz, M.Z.2
Carroll, R.R.3
-
19
-
-
0036467835
-
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
-
Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-31.
-
(2002)
J Clin Oncol
, vol.20
, pp. 727-731
-
-
Holmes, F.A.1
O'Shaughnessy, J.A.2
Vukelja, S.3
-
20
-
-
84891724520
-
-
Available at:, Accessed January 26, 2007
-
FDA approved label for Neulasta. Available at: http://www.fda.gov/Cder/ biologics/products/pegfamg013102.htm. Accessed January 26, 2007.
-
FDA approved label for Neulasta
-
-
-
21
-
-
85039213900
-
-
Available at:, Accessed March 16, 2007
-
FDA approval for Neupogen. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm. Accessed March 16, 2007.
-
FDA approval for Neupogen
-
-
-
22
-
-
0027732691
-
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
-
Glaspy J, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(suppl 7): S23-S30.
-
(1993)
Eur J Cancer
, vol.29 A
, Issue.SUPPL. 7
-
-
Glaspy, J.1
Bleecker, G.2
Crawford, J.3
-
23
-
-
33644833866
-
Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: Findings from a large population-based cohort
-
Du XL, Lairson DR, Begley CE, et al. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol. 2005;23:8620-28.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8620-8628
-
-
XL, D.1
Lairson, D.R.2
Begley, C.E.3
-
24
-
-
0032703442
-
Use of hematopoietic colonystimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology
-
Bennett CL, Weeks JA, Somerfield MR, et al. Use of hematopoietic colonystimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999;17:3676-81.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3676-3681
-
-
Bennett, C.L.1
Weeks, J.A.2
Somerfield, M.R.3
-
25
-
-
0142240826
-
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy
-
Available at:, Accessed April 22
-
Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm. 2003;9(2)(suppl): 15-21. Available at: http://www.amcp.org/data/jmcp/index_suppv21.pdf. Accessed April 22, 2007.
-
(2007)
J Manag Care Pharm. 2003
, vol.9
, Issue.2 SUPPL.
, pp. 15-21
-
-
Scott, S.D.1
Chrischilles, E.A.2
Link, B.K.3
-
26
-
-
85039238890
-
Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. Poster
-
presented at: December 7-11, New Orleans, LA
-
Former B, Stolshek B, Mao Q, et al. Association of IV antibiotic use and hospitalization with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. Poster presented at: 38th ASHP Midyear Clinical Meeting and Exhibition; December 7-11, 2003; New Orleans, LA.
-
(2003)
38th ASHP Midyear Clinical Meeting and Exhibition
-
-
Former, B.1
Stolshek, B.2
Mao, Q.3
-
27
-
-
0034003365
-
Growth factor usage patterns and outcomes in the community setting: Collection through a practice-based computerized clinical information system
-
Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18:1764-70.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1764-1770
-
-
Swanson, G.1
Bergstrom, K.2
Stump, E.3
-
28
-
-
0142157169
-
Evaluating medication effects outside of clinical trials: New-user designs
-
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20.
-
(2003)
Am J Epidemiol
, vol.158
, pp. 915-920
-
-
Ray, W.A.1
-
29
-
-
84992750713
-
-
Available at:, Accessed December 5, 2005
-
IMS Health Web site. Available at: http://www.imshealth.com/. Accessed December 5, 2005.
-
IMS Health Web site
-
-
-
30
-
-
0023092594
-
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
-
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
-
(1987)
J Chronic Dis
, vol.40
, pp. 373-383
-
-
Charlson, M.E.1
Pompei, P.2
Ales, K.L.3
-
31
-
-
85039225306
-
-
U.S. Dept. of Health and Human Services: Health Insurance Portability and Accountability Act (HIPAA). Available at: http://www.hhs.gov/ocr/ hipaa/. Accessed May 3, 2007.
-
U.S. Dept. of Health and Human Services: Health Insurance Portability and Accountability Act (HIPAA). Available at: http://www.hhs.gov/ocr/ hipaa/. Accessed May 3, 2007.
-
-
-
-
33
-
-
33745989223
-
Recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline; 2006 update
-
Smith TC, Khatcheressian J, Lyman G, et al. Recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline; 2006 update. J Clin Oncol. 2006;24:1-19,3187-3205.
-
(2006)
J Clin Oncol
, vol.24
-
-
Smith, T.C.1
Khatcheressian, J.2
Lyman, G.3
-
34
-
-
28244502087
-
Observational studies of drugs and mortality
-
Ray WA. Observational studies of drugs and mortality. N Engl J Med. 2005;353:2319-21.
-
(2005)
N Engl J Med
, vol.353
, pp. 2319-2321
-
-
Ray, W.A.1
-
35
-
-
0033847784
-
Marginal structural models and causal inference in epidemiology
-
Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-60.
-
(2000)
Epidemiology
, vol.11
, pp. 550-560
-
-
Robins, J.M.1
Hernan, M.A.2
Brumback, B.3
-
36
-
-
77649173768
-
Longitudinal data analysis using generalized linear models
-
Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
-
(1986)
Biometrika
, vol.73
, pp. 13-22
-
-
Liang, K.1
Zeger, S.2
-
37
-
-
10344230139
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
-
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-11.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4302-4311
-
-
Lyman, G.H.1
Dale, D.C.2
Friedberg, J.3
Crawford, J.4
Fisher, R.I.5
-
38
-
-
1542753592
-
Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
-
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-31.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4524-4531
-
-
Lyman, G.H.1
Dale, D.C.2
Crawford, J.3
-
39
-
-
33746904664
-
-
National Comprehensive Cancer Network, Version 1.2007. Available at:, Accessed January 26
-
National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology Myeloid growth factors. Version 1.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed January 26, 2007.
-
(2007)
NCCN clinical practice guideline in oncology Myeloid growth factors
-
-
-
40
-
-
85039182821
-
-
Agency for Healthcare Research and Quality Outcomes of Pharmaceutical Therapy Program (OPT) update. AHRQ Publication No. 04-R205, Agency for Healthcare Research and Quality, Rockville, MD: Agency for Healthcare Research and Quality Available at: http://www.ahrq.gov/clinic/ pharmtherapy/optupdat.htm. Accessed June 2004.
-
Agency for Healthcare Research and Quality Outcomes of Pharmaceutical Therapy Program (OPT) update. AHRQ Publication No. 04-R205, Agency for Healthcare Research and Quality, Rockville, MD: Agency for Healthcare Research and Quality Available at: http://www.ahrq.gov/clinic/ pharmtherapy/optupdat.htm. Accessed June 2004.
-
-
-
|